Regeneron Pharmaceuticals
Prezzo: 612.14Società e modello di business
Regeneron Pharmaceuticals is a biotechnology company focused on the discovery, development, and commercialization of innovative medicines for serious diseases. Its core products include EYLEA, a treatment for eye diseases, and REGEN-COV, a COVID-19 therapy. The company operates primarily in the healthcare sector, with major revenue sources stemming from product sales and collaborations. Regeneron invests heavily in research and development to expand its portfolio and pipeline of therapies.
Profilo di investimento
The investment profile of Regeneron Pharmaceuticals is more aligned with growth investors due to its focus on innovation and potential for future revenue increases. The company offers a modest dividend yield, appealing to those seeking some income, but its primary appeal lies in growth potential. The stock may be more suitable for medium to long-term investors who can tolerate volatility.
Metriche fondamentali (sperimentale)
- EPS (TTM) — utile per azione degli ultimi 12 mesi, $
- 42.53 OK
- Ricavi QoQ — crescita dei ricavi trimestre su trimestre
- -7.2% ↓
- Sorpresa EPS
- 6.3% meglio del previsto
- Volatilità 20g
- 2.6% stabile
- Rendimento dividendo
- 0.6% basso ultima data ex-dividendo: 2026-05-20
Impatto della previsione
negativoTraccia in portafoglio
Grafico prezzo
| Data | Prima | Dopo | Motivo |
|---|---|---|---|
| 2026-06-03 02:51 | Mantieni | Vendi | Weak momentum and fundamentals raise significant risk. |
| 2026-05-24 02:48 | Vendi | Mantieni | Weak momentum and fundamentals raise significant risk. |
| 2026-05-16 02:34 | Mantieni | Vendi | Weak fundamentals and negative momentum raise concerns. |
| Data | Analista | Action | Target | Prezzo allora |
|---|---|---|---|---|
| 2026-05-19 10:43 | Canaccord Genuity | Target abbassato | 1057 → 875 | 629.68 |
| 2026-05-18 18:48 | Wolfe Research | Target abbassato | 900 → 860 | 629.36 |
| 2026-05-18 12:40 | Evercore ISI | Target abbassato | 875 → 825 | 619.84 |
Ancora nulla